Countdown for AIDS treatment overcoming ‘Stribild’ to launch in Korea

A Gilead Sciences’ new 4-substance complex drug ‘Genvoya’ acquired approval to commercialize in Korea. Thus, Gilead is expected to consolidate its position in the HIV treatment market.

According to the industry concerned on the 20^th, the Ministry of Food and Drug Safety recently approved commercialization of Genvoya(elvitegravir, emtricitabine, tenofovir alafenaminde fumarate, cobicistat).